Published in J Invest Dermatol on July 01, 2001
IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol (2011) 1.07
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol (2003) 1.07
Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am J Pathol (2005) 0.82
Phytochemicals for the Management of Melanoma. Mini Rev Med Chem (2016) 0.77
Fad104, a positive regulator of adipocyte differentiation, suppresses invasion and metastasis of melanoma cells by inhibition of STAT3 activity. PLoS One (2015) 0.76
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J (1998) 7.15
Imaging and tracking of single GFP molecules in solution. Biophys J (2000) 4.82
PIP2 and PIP as determinants for ATP inhibition of KATP channels. Science (1998) 3.88
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem (1992) 3.48
Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol (1993) 3.37
Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology (1990) 3.27
Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today (1998) 3.12
Intracellular anions as the voltage sensor of prestin, the outer hair cell motor protein. Science (2001) 2.99
Murine epidermal cell-derived thymocyte-activating factor resembles murine interleukin 1. J Immunol (1982) 2.90
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett (1989) 2.79
Epidermal cell (keratinocyte)-derived thymocyte-activating factor (ETAF). J Immunol (1981) 2.74
Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell (2000) 2.70
Control of proteolysis. Annu Rev Biochem (1980) 2.67
Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med (1990) 2.62
Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol (2006) 2.49
Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett (1988) 2.39
The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol (1994) 2.26
Identification of a titratable lysine residue that determines sensitivity of kidney potassium channels (ROMK) to intracellular pH. EMBO J (1996) 2.21
SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem (2000) 2.14
Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with darier's disease. Clin Infect Dis (2001) 2.14
Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol (2010) 2.12
Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS Lett (1987) 2.04
Chemotactic properties of partially purified human epidermal cell-derived thymocyte-activating factor (ETAF) for polymorphonuclear and mononuclear cells. J Immunol (1983) 2.03
The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol (1993) 2.01
Anthraquinone production by cell suspension cultures of Morinda citrifolia. Planta Med (1975) 1.95
Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur J Immunol (1988) 1.95
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol (1992) 1.94
Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today (1995) 1.91
Regulation of apoptosis in the immune system. Curr Opin Immunol (1994) 1.89
Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol (1999) 1.81
Action of recombinant human interleukin 6, interleukin 1 beta and tumor necrosis factor alpha on the mRNA induction of acute-phase proteins. Eur J Immunol (1988) 1.76
Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol (1998) 1.75
Expression of suppressors of cytokine signaling during liver regeneration. J Clin Invest (2001) 1.71
The signalling pathways of interleukin-6 and gamma interferon converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol Cell Biol (1994) 1.70
Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem (1988) 1.69
Circular dichroism of ribonucleoprotein complexes from rat liver nuclei. Biochem Biophys Res Commun (1977) 1.69
Extracellular K+ and intracellular pH allosterically regulate renal Kir1.1 channels. J Biol Chem (1996) 1.68
The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol Cell Biol (1994) 1.67
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Visualization of nuclear pore complex and its distribution by confocal laser scanning microscopy. Methods Enzymol (1999) 1.66
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol (2008) 1.64
Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy. Br J Dermatol (2013) 1.63
The role of APO-1-mediated apoptosis in the immune system. Immunol Rev (1994) 1.59
IFN-beta 2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. J Immunol (1989) 1.54
Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos (2009) 1.53
Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol Cell Biol (1997) 1.51
Heat shock protein 70 overexpression affects the response to ultraviolet light in murine fibroblasts. Evidence for increased cell viability and suppression of cytokine release. J Clin Invest (1995) 1.49
Evidence for an epidermal cytokine network. J Invest Dermatol (1990) 1.48
A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J Biol Chem (1996) 1.47
LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett (1999) 1.46
Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation. Mol Cell Biol (1989) 1.43
STAT3 is constitutively activated in Hodgkin cell lines. Blood (2001) 1.42
[Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients]. Hautarzt (2004) 1.42
Ultraviolet light induces increased circulating interleukin-6 in humans. J Invest Dermatol (1990) 1.42
[Drug reaction to amoxicillin simulating toxic pustuloderma]. Hautarzt (1991) 1.42
Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene (1995) 1.41
Molecular mechanisms of UV-induced apoptosis. Photodermatol Photoimmunol Photomed (2000) 1.41
Diagnosis of bone infection using 99m Tc-HMPAO labelled leukocytes. Nucl Med Commun (2001) 1.40
Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol (1998) 1.40
Treatment of urticaria pigmentosa using interferon alpha. Br J Dermatol (1995) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Valve surgery combined with coronary artery operation: is the use of internal mammary artery a predictor for early complications? Eur J Cardiothorac Surg (1996) 1.39
Validation of Dermaphot(®) for the assessment of steroid-induced skin atrophy. Arch Dermatol Res (2012) 1.38
Responder cells in the human autologous mixed lymphocyte reaction. J Clin Invest (1981) 1.37
Effect of swainsonine on the processing of the asparagine-linked carbohydrate chains of alpha 1-antitrypsin in rat hepatocytes. Evidence for the formation of hybrid oligosaccharides. J Biol Chem (1983) 1.35
The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax. J Biol Chem (2001) 1.33
Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture. J Clin Invest (1982) 1.33
The chromatin structure of the dual c-myc promoter P1/P2 is regulated by separate elements. J Biol Chem (2001) 1.32
Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur J Biochem (1988) 1.31
Precision top-quark mass measurement at CDF. Phys Rev Lett (2012) 1.30
Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest (1994) 1.29
MiRNA-29: a microRNA family with tumor-suppressing and immune-modulating properties. Curr Mol Med (2013) 1.28
Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol (2008) 1.28
Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem J (1998) 1.28
IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol (1989) 1.28
1-deoxynojirimycin impairs oligosaccharide processing of alpha 1-proteinase inhibitor and inhibits its secretion in primary cultures of rat hepatocytes. J Biol Chem (1983) 1.27
Inward rectification in KATP channels: a pH switch in the pore. EMBO J (1999) 1.27
Increased thymocyte-activating factor in human gingival fluid during gingival inflammation. Infect Immun (1982) 1.27
In vitro correction of the interleukin 2 defect of autoimmune mice. Eur J Immunol (1983) 1.27
Interleukin-6-induced serine phosphorylation of transcription factor APRF: evidence for a role in interleukin-6 target gene induction. FEBS Lett (1995) 1.26
The expression and modulation of IL-1 alpha in murine keratinocytes. J Immunol (1988) 1.25
Development of a human interleukin-6 receptor antagonist. J Biol Chem (1994) 1.25
Mycosis fungoides: a dermatological masquerader. Br J Dermatol (2007) 1.24
Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene (1999) 1.24
Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity. J Immunol (1995) 1.24